‘DURVIT’: a phase-I trial of single low-dose durvalumab (Medi4736) IntraTumourally injected in cervical cancer: safety, toxicity and effect on the primary tumour- and lymph node microenvironment

Treatment with programmed cell death receptor (PD-1) and programmed cell death ligand 1 (PD-L1) inhibitors is a promising strategy to lift tumour-induced immune response suppression. However, the current syste...

Source: BMC Cancer - September 12, 2018 Category: Cancer & Oncology Authors: J. Rotman, C. H. Mom, E. S. Jordanova, T. D. de Gruijl and G. G. Kenter Tags: Study protocol Source Type: research